Conpelisib

康培利司

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NameConpelisib
Drug Alias NamePI3 Kinase p110β/δ inhibitor (Fukang)CVL237KA-2237CVL-237
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase beta inhibitorsPhosphatidylinositol 3 kinase delta inhibitors
TargetsPhosphatidylinositol 3 kinase betaPhosphatidylinositol 3 kinase delta
Therapy Area/IndicationsSolid tumoursActivated PI3K-delta syndromeUterine Cervical Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesConvalife (Shanghai) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesConvalife (Shanghai) Co LtdZhejiang Fukang Pharmaceutical Co LtdThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesKarus Therapeutics Ltd
Active IndicationsSolid tumoursActivated PI3K-delta syndromeUterine Cervical Neoplasms +[11] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A